InspireMD Inc. Series B Warrants (NSPRZ)
$0.01
$0.00
(22.86%)
As on 14-Mar-2022 15:58EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
6 Years Aggregate
CFO
$-55.33 Mln
EBITDA
$-50.05 Mln
Net Profit
$-59.64 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
InspireMD Inc. Series B Warrants (NSPRZ)
| -89.9 | -85.1 | -89.9 | -- | -- | -- | -- |
|
BSE Sensex*
| -11.7 | -4.8 | 1.7 | -7.5 | 3.9 | 5.1 | 9.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout InspireMD Inc. Series B Warrants (NSPRZ)
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The... company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel. Read more
-
Pres, CEO & Director
Mr. Marvin L. Slosman
-
Pres, CEO & Director
Mr. Marvin L. Slosman
-
Headquarters
Tel Aviv
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for InspireMD Inc. Series B Warrants (NSPRZ)
What is the current share price of InspireMD Inc Series B Warrants (NSPRZ) Today?
The share price of InspireMD Inc Series B Warrants (NSPRZ) is $0.01 (NASDAQ) as of 14-Mar-2022 15:58 EDT. InspireMD Inc Series B Warrants (NSPRZ) has given a return of --% in the last 1 years.
What is the current PB & PE ratio of InspireMD Inc Series B Warrants (NSPRZ)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2021 |
-0.05 |
0.02 |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
2017 |
-- |
-- |
What is the 52 Week High and Low of InspireMD Inc Series B Warrants (NSPRZ)?
The 52-week high and low of InspireMD Inc Series B Warrants (NSPRZ) are Rs -- and Rs -- as of 09-Sep-2026.
What is the market cap of InspireMD Inc Series B Warrants (NSPRZ)?
InspireMD Inc Series B Warrants (NSPRZ) has a market capitalisation of $ 41 Mln as on 14-Mar-2022. As per SEBI classification, it is a company.
Should I invest in InspireMD Inc Series B Warrants (NSPRZ)?
Before investing in InspireMD Inc Series B Warrants (NSPRZ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.